<DOC>
	<DOCNO>NCT02409186</DOCNO>
	<brief_summary>Esophageal cancer sixth lead cause cancer death worldwide . Over past 2 decade , well-designed clinical trial document clinical benefit combination chemotherapy radiation localize esophageal cancer , either primary therapy neoadjuvant setting . Paclitaxel , radiation sensitizer , important single-agent activity esophageal cancer . Paclitaxel-based chemoradiation framework recent Radiation Therapy Oncology Group ( RTOG ) trial nonoperative management esophageal cancer . Accumulating clinical evidence suggest Epidermal Growth Factor Receptor ( EGFR ) represent viable target treatment esophageal cancer . EGFR expression associate poor prognosis . Nimotuzumab bind specifically EGFR normal tumor cell competitively inhibit bind Epidermal Growth Factor ( EGF ) ligands , Transforming Growth Factor-α ( TGF-α ) . Preclinical model suggest synergy nimotuzumab , paclitaxel , cisplatin radiation . For phase II study locally advance esophageal squamous cell carcinoma ( ESCC ) , combination cetuximab chemoradiotherapy demonstrate response survival benefit . Myara et al report nimotuzumab plus concurrent chemoradiation therapy ( CCRT ) safe provide statistically significant objective response ( 47.8 % ) disease control rate ( 60.9 % ) nonresectable ESCC . With , investigator plan study phase III trial .</brief_summary>
	<brief_title>A Phase III Study Nimotuzumab Plus Concurrent Chemoradiotherapy Loco-regional Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>The primary endpoint study overall survival , primary hypothesis experimental arm improve median survival time ( MST ) 18.2 month 28.5 month . Assuming bilateral ɑ = 0.05 , statistical power 80 % .Each group require minimum 59 case . Consider 20 % loss factor.The total sample size 200 cases.It 100 case group .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Prosthesis Failure</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Signed write informed consent prior study entry 2. age：1870 year 3 . Histopathology confirm primary esophageal squamous cell carcinoma , meet one follow criterion ( AJCC Staging System，2009，Seventh Edition ) : Cervical esophageal carcinoma ( stage IIIII ) ; upper thoracic esophageal cancer chest esophageal cancer unsuitable refuse surgery ( stage IIIII ) 4 . The existence measurable lesion ( accord Response Evaluation Criteria Solid Tumors 1.1 ) 5 . Eastern Cooperative Oncology Group（ECOG）Performance status 01 6 . Possible semiliquid diet 7 . If risk pregnancy , male female subject must effective contraception treatment 8 . Normal bone marrow reserve : neutrophil ( ANC ) count≥1500/mm3 , platelet count≥100,000 /mm3 , hemoglobin≥5.6mmol/L ( 9g/dL ) 9 . Normal renal function : serum creatinine≤1.5mg/dl and/or calculate creatinine clearance≥ 60ml/min 10 . Normal hepatic function : bilirubin level≤1.5×ULN , alanine aminotransferase aspartate transaminase（ASAT） &amp; ALST≤1.5×ULN 11 . Subjects tumor tissue available relevant biomarker detection 1 . Previous chest radiotherapy , systemic chemotherapy , major esophageal surgery 2 . Concurrent chronic systemic immune therapy , target therapy , antivascular endothelial growth factor（VEGF）therapy EGFRpathway target therapy indicate study protocol 3 . Multiple primary carcinoma esophagus 4 . Pregnancy ( confirm urine βHCG ) lactation period 5 . Uncontrolled diabetes , hypertension , severe cardiac pulmonary disease 6 . There obvious esophageal ulcer , chest back moderate pain , symptom esophageal perforation 7 . Unable comprehend study requirement likely comply study requirement 8 . Patients distant metastasis 9 . Patients malignant disease , except curable nonmelanoma skin cancer , cervical carcinoma situ malignant disease cure for≥5 year 10 . Known grade 3 4 allergic reaction study treatment 11 . Peripheral neuropathy &gt; grade 1 12 . Participation another clinical study within past 30 day 13 . Significant disease , investigator 's opinion , would exclude patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>